Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ioGenetics is a private biotechnology company based in Madison, Wisconsin focused on infectious-disease therapeutics, vaccines, diagnostics, and immunoinformatics. The company describes an integrated recombinant-protein pipeline and has emphasized proprietary antimicrobial proteins, including anticryptosporidial, antistaphylococcal, and antiviral products. Its technology base appears to include the RPex retrovector platform for producing novel antibodies and antibody-fusion proteins, as well as immunoinformatics capabilities associated with uTOPE and its subsidiary EigenBio. Publicly available information suggests the company remains small, private, and primarily preclinical, with licensing and partnering interest around its protein technologies and intellectual property portfolio. ioGenetics appears best characterized as an early-stage platform-oriented biotech rather than a clinical-stage drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ioGenetics.